CLEOPATTRANNC6019-0001 for Transthyretin Amyloid Cardiomyopathy
NNC6019-0001
+ Placebo (NNC6019-0001)
Treatment Study
Summary
Study start date: October 2, 2025
Actual date on which the first participant was enrolled.This study aims to explore whether a new medication called NNC6019-0001 can lower the risk of heart-related death and illness in people with a heart condition known as transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a disease that affects the heart's structure and function, leading to serious heart problems. The study is important because it seeks to find better treatment options for those with this condition, potentially improving their quality of life and survival rates. Participants in the study will be randomly assigned to receive either the new medication NNC6019-0001 or a placebo, which is an inactive substance. This ensures that the study results are unbiased and reliable. All participants will continue with their standard heart treatments as advised by their healthcare providers. The study will look at how well NNC6019-0001 works compared to the placebo in reducing heart-related health issues, but no specific outcomes are listed. There are no specific risks or benefits mentioned for participants in this description.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.1280 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 285 locations
Hospital Universitario Reina Sofia
Córdoba, SpainOpen Hospital Universitario Reina Sofia in Google MapsHospital Universitario Ramon y Cajal
Madrid, SpainHospital Universitario La Paz
Madrid, SpainHospital Universitario Puerta de Hierro de Majadahonda
Majadahonda, Spain